Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.52 |
| ▸ | FYN | P06241 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479730 | 0.95 | MAPT (0.67) | MAPTCASP1PDGFRBPDGFRAFPR2 | |
| SCHEMBL15577455 | 0.87 | PDGFRB (0.64) | MAPTCASP1PDGFRBPDGFRAFPR2 | |
| SCHEMBL14551155 | 0.85 | KIT (0.53) | MAPTCASP1PDGFRBPDGFRAFPR2 | |
| SCHEMBL30129857 | 0.84 | FYN (0.60) | MAPTCASP1PDGFRBPDGFRAFPR2 | |
| SCHEMBL17016686 | 0.82 | MAPT (0.55) | MAPTCASP1PDGFRBPDGFRAPIK3CA | |
| SCHEMBL15577625 | 0.80 | KIT (0.57) | FPR2AAK1KIT | |
| SCHEMBL5183178 | 0.79 | PDGFRB (0.59) | MAPTCASP1PDGFRBPDGFRAPIK3CA | |
| SCHEMBL17016700 | 0.79 | PDGFRB (0.59) | MAPTCASP1PDGFRBPDGFRAPIK3CA | |
| SCHEMBL23249841 | 0.79 | FPR2 (0.50) | MAPTCASP1PDGFRBPDGFRAFPR2 | |
| SCHEMBL29890158 | 0.79 | FPR2 (0.50) | MAPTCASP1PDGFRBPDGFRAFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309199-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309199-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2016-04-12 | — | — | US | disclosed |
| CN-102933079-A | catechol-O-methyltransferase inhibitors and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME | 2013-02-13 | — | — | CN | disclosed |
| EP-2542077-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | Merck Sharp & Dohme Corp. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-01-03 | — | — | US | disclosed |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-01-03 | — | — | US | disclosed |
| WO-2011109261-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | MAPT 220/4885CASP1 4086/4885PDGFRB 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.